Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Idecabtagene Vicleucel Approved in Japan for Relapsed/Refractory Multiple Myeloma

January 20th 2022

The Japanese Ministry of Health, Labour, and Welfare has approved idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma, who have previously received at least 3 therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have progressed on their last therapy or relapsed following their last therapy.

Dr. Finn on the Utility of Belantamab Mafodotin in Late Relapsed Multiple Myeloma

January 17th 2022

Laura Finn, MD, discusses the utility of belantamab mafodotin-blmf in late relapsed multiple myeloma.

Selecting the Optimal Treatment Approach for Difficult-to-Treat, Relapsed/Refractory Myeloma

January 14th 2022

Certain patient and disease characteristics must be considered to select the optimal treatment approach for difficult-to-treat patients with relapsed or refractory multiple myeloma.

Wealth of Newer Treatment Options Span the Scope of Multiple Myeloma and Amyloidosis

January 13th 2022

Tomer Mark, MD, discusses the emerging role of minimal residual disease as a surrogate end point in multiple myeloma, treatment selection for patients with newly diagnosed, early relapsed, and late relapsed disease, and the importance of daratumumab being introduced to the treatment paradigm of amyloidosis.

Triplet and Quadruplet Regimens Set a New Course for Myeloma

January 11th 2022

When treating cancers that are considered generally incurable, such as multiple myeloma, one of the paradigms in oncology is to deliver the most effective therapies upfront to maximize the chances of prolonging remission.

Dr. Vogl on the Utilization of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma

January 7th 2022

Dan Vogl, MD, MSCE, discusses the utilization of modakafusp alfa in relapsed/refractory multiple myeloma.

Dr. Mark on Questions Regarding Sequencing in Multiple Myeloma

January 5th 2022

Tomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.

Dr. Sherbenou on Selecting Treatment in Late Relapsed Multiple Myeloma

January 5th 2022

Daniel Sherbenou, MD, PhD, discusses selecting between available treatment options for patients with late relapsed multiple myeloma.

Dr. Larocca on Treatment Considerations for Difficult-to-Treat, Relapsed/Refractory Myeloma

January 3rd 2022

Alessandra Larocca, MD, PhD, discusses the various factors to consider when selecting treatment for difficult-to-treat patients with relapsed/refractory multiple myeloma.

Novel Agents Help Bridge Gaps in Care in Multiple Myeloma

December 31st 2021

Naresh Bumma, MD, discusses the focus of each presentation on frontline therapy, early and late relapse, and CAR T-cell therapy in multiple myeloma.

Questions on Quadruplets and CAR T Set to be Answered As Myeloma Paradigm Parses Out the Clinical Value of MRD

December 30th 2021

The armamentarium of multiple myeloma has expanded with the introduction of combination regimens in the up-front setting and novel targeted agents, including CAR T-cell therapy, in the relapsed/refractory setting.

FDA Approval Sought for Teclistamab for Relapsed/Refractory Multiple Myeloma

December 29th 2021

A biologics license application seeking the approval of teclistamab for use in patients with relapsed or refractory multiple myeloma has been submitted to the FDA.

Multiple Myeloma Paradigm Adapts to Novel Therapies Across Disease States

December 29th 2021

Data from key clinical trials evaluating expanded combination strategies and novel therapies have transformed the treatment paradigms of newly diagnosed, relapsed/refractory, and heavily pretreated multiple myeloma, but it remains important to contextualize the data appropriately without cross-trial comparisons.

Gasparetto Talks Management Strategies for Belantamab Mafodotin–Related Ocular Toxicity in Myeloma

December 27th 2021

Dr Gasparetto discusses the management of ocular toxicities associated with belantamab mafodotin, the nuances of dose modification, and the potential for retreatment following toxicity resolution.

Dr. Sherbenou on Future Directions With Maintenance Therapy in Multiple Myeloma

December 23rd 2021

Daniel Sherbenou, MD, PhD, discusses future directions with maintenance therapy in patients with relapsed/refractory multiple myeloma who received CAR T-cell therapy.

Selinexor Approved in China for Relapsed or Refractory Multiple Myeloma

December 22nd 2021

The China National Medical Products Administration has granted a conditional marketing approval to selinexor for use in combination with dexamethasone in patients with relapsed or refractory multiple myeloma who have previously received treatment and whose disease is refractory to at least a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Clinical Case 1: 69-Year-Old Man With Multiple Myeloma (MM)

December 22nd 2021

Expert hematologist/oncologists review the case of a 69-year-old man with multiple myeloma who had a biochemical relapse and share their approaches to treatment.

Belantamab Mafodotin/Pd Triplet Demonstrates Manageable Safety Profile in Relapsed/Refractory Myeloma

December 17th 2021

The triplet regimen of belantamab mafodotin plus pomalidomide and dexamethasone was revealed to have a manageable safety profile, which is consistent with the known individual safety profiles of belantamab mafodotin or pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma.

Dr. Mouhieddine on Outcomes After Bispecific Antibodies in R/R Multiple Myeloma